{"article": ["you raise a good point- according to some estimates, the biotech industry (not including traditional big pharma) has on net yet to make a profit: [biotech's dismal bottom line: more than $40 billion in losses] ( i think it's somewhat better in the traditional small molecule drug world, but it's getting worse there now, as the endless wailing and gnashing of teeth in the pharma/chemistry blog world attests.", "however, while it is of course true that failure is a part of research, one tries very hard to reduce the amount of failure, whether in industry or academe, and i don't think that the biopharma companies are really more failure averse than the funding agencies; when writing a grant you generally need to have already done enough work on the project to convince the approval committees that you're bound to succeed, and those committees are notoriously averse to high risk, high reward projects.", "i'm not sure if there's a way around this; the two models we have now (industry and academics)  kinda  work, maybe they could be less risk averse, but then, well, failure costs money, and since we already fail enough, maybe we should be cautious about encouraging more failure.", "the one thing i do think would be nice is more diversity in funding and less centralization.", "when you're bound to fail a lot anyway, having monolithic decision making about what projects to fund seems like a recipe for getting larger, more painful failures, whether in giant consolidated biopharma companies or giant consolidated federal funding agencies.", "scientific [monoculture] ( as it were."], "abstract": ["fear of failure is bad, but too much failure is bad too, and right now it seems like pharma's having more problems with endless failure than they are with risk aversion."], "candidates": [[["according to some estimates, the biotech industry has on net yet to make a profit.", "the biotech industry (not including traditional big pharma) has onnet yet to made a profit: more than $40 billion in losses."], 0.05882352941176471], [["according to some estimates, the biotech industry has on net yet to make a profit.", "the biotech industry (not including traditional big pharma) has onnet yet to made a profit: more than $40 billion in losses.", "i"], 0.057971014492753624], [["barry rosen: biotech industry has yet to make a profit.", "he says it's better in small molecule drug world but it's getting worse in big pharma.", "rosen: more diversity in funding and less centralization would be nice."], 0.09389671361502348], [["biotech industry has yet to make a profit, according to some estimates.", "one thing that would be nice is more diversity in funding and less centralization."], 0.0574712643678161], [["biotech's dismal bottom line: more than $40 billion in losses.", "one thing i do think would be nice is more diversity in funding and less centralization."], 0.11299435028248588], [["biotech industry has yet to make a profit, according to some estimates.", "the industry is more risk averse than funding agencies, says author.", "more diversity in funding and less centralization would be nice, he says."], 0.1197091465748182], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies.", "more diversity in funding would be nice.", "the two models we have now (industry and academics) kinda work."], 0.1621848739495798], [["biotech has yet to make a profit, according to some estimates.", "the industry is more risk averse than funding agencies, says dr. david perry.", "perry: more diversity in funding and less centralization would be nice."], 0.1197091465748182], [["according to some estimates, the biotech industry has on net yet to make a profit.", "while it is of course true that failure is a part of research, one tries very hard to reduce the amount of failure."], 0.11484593837535013], [["some estimates say biotech industry has yet to make a profit.", "biopharma companies are more failure averse than funding agencies, says author.", "more diversity in funding and less centralization would be nice, he says."], 0.101010101010101], [["according to some estimates, the biotech industry (not including traditional big pharma) has on net yet to make a profit."], 0.025641025641025644], [["the biotech industry has on net yet to make a profit.", "the one thing i do think would be nice is more diversity in funding and less centralization."], 0.05555555555555555], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies.", "more diversity in funding would be nice."], 0.1472891267717316], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies."], 0.16717948717948716], [["some estimates say biotech industry has yet to make a profit.", "biopharma companies are more failure averse than funding agencies, says author."], 0.09876543209876543], [["biotech's dismal bottom line: more than $40 billion in losses."], 0.09302325581395349]], "article_untok": ["you raise a good point- according to some estimates, the biotech industry (not including traditional big pharma) has on net yet to make a profit: [biotech's dismal bottom line: more than $40 billion in losses] ( i think it's somewhat better in the traditional small molecule drug world, but it's getting worse there now, as the endless wailing and gnashing of teeth in the pharma/chemistry blog world attests.", "however, while it is of course true that failure is a part of research, one tries very hard to reduce the amount of failure, whether in industry or academe, and i don't think that the biopharma companies are really more failure averse than the funding agencies; when writing a grant you generally need to have already done enough work on the project to convince the approval committees that you're bound to succeed, and those committees are notoriously averse to high risk, high reward projects.", "i'm not sure if there's a way around this; the two models we have now (industry and academics)  kinda  work, maybe they could be less risk averse, but then, well, failure costs money, and since we already fail enough, maybe we should be cautious about encouraging more failure.", "the one thing i do think would be nice is more diversity in funding and less centralization.", "when you're bound to fail a lot anyway, having monolithic decision making about what projects to fund seems like a recipe for getting larger, more painful failures, whether in giant consolidated biopharma companies or giant consolidated federal funding agencies.", "scientific [monoculture] ( as it were."], "abstract_untok": ["fear of failure is bad, but too much failure is bad too, and right now it seems like pharma's having more problems with endless failure than they are with risk aversion."], "candidates_untok": [[["according to some estimates, the biotech industry has on net yet to make a profit.", "the biotech industry (not including traditional big pharma) has onnet yet to made a profit: more than $40 billion in losses."], 0.05882352941176471], [["according to some estimates, the biotech industry has on net yet to make a profit.", "the biotech industry (not including traditional big pharma) has onnet yet to made a profit: more than $40 billion in losses.", "i"], 0.057971014492753624], [["barry rosen: biotech industry has yet to make a profit.", "he says it's better in small molecule drug world but it's getting worse in big pharma.", "rosen: more diversity in funding and less centralization would be nice."], 0.09389671361502348], [["biotech industry has yet to make a profit, according to some estimates.", "one thing that would be nice is more diversity in funding and less centralization."], 0.0574712643678161], [["biotech's dismal bottom line: more than $40 billion in losses.", "one thing i do think would be nice is more diversity in funding and less centralization."], 0.11299435028248588], [["biotech industry has yet to make a profit, according to some estimates.", "the industry is more risk averse than funding agencies, says author.", "more diversity in funding and less centralization would be nice, he says."], 0.1197091465748182], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies.", "more diversity in funding would be nice.", "the two models we have now (industry and academics) kinda work."], 0.1621848739495798], [["biotech has yet to make a profit, according to some estimates.", "the industry is more risk averse than funding agencies, says dr. david perry.", "perry: more diversity in funding and less centralization would be nice."], 0.1197091465748182], [["according to some estimates, the biotech industry has on net yet to make a profit.", "while it is of course true that failure is a part of research, one tries very hard to reduce the amount of failure."], 0.11484593837535013], [["some estimates say biotech industry has yet to make a profit.", "biopharma companies are more failure averse than funding agencies, says author.", "more diversity in funding and less centralization would be nice, he says."], 0.101010101010101], [["according to some estimates, the biotech industry (not including traditional big pharma) has on net yet to make a profit."], 0.025641025641025644], [["the biotech industry has on net yet to make a profit.", "the one thing i do think would be nice is more diversity in funding and less centralization."], 0.05555555555555555], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies.", "more diversity in funding would be nice."], 0.1472891267717316], [["the biotech industry is losing more than $40 billion a year.", "the industry is more risk averse than funding agencies."], 0.16717948717948716], [["some estimates say biotech industry has yet to make a profit.", "biopharma companies are more failure averse than funding agencies, says author."], 0.09876543209876543], [["biotech's dismal bottom line: more than $40 billion in losses."], 0.09302325581395349]]}